Chinese Innovative Drug Stocks Slip; Beijing Hotgen Biotech Falls Over 10%

The absence of a named catalyst is itself the signal: a broad, double-digit drop in one innovative-drug name alongside 5%+ declines across several peers points to sector-wide de-risking rather than company-specific news. That pattern matters because it suggests positioning and sentiment, not fundamentals, are driving flows — a distinction that affects how much weight to give any single stock's move. Whether the correction stays contained to these names or spreads further across Chinese biotech is the open question.